Artificial Intelligence in the Breast Pathology: The Future is Here (USCAP 2026)

In this presentation from the Ibex symposium at USCAP 2026, Professor Stuart Schnitt, MD, Chief of the Division of Cancer Pathology at Beth Israel Deaconess Medical Center, discusses how the integration of AI is actively transforming the field of breast pathology. Dr. Schnitt evaluates the clinical utility of Ibex Breast, highlighting its high diagnostic accuracy across benign lesions, DCIS, and invasive cancer, including the identification of the smallest foci of invasion. The session details how AI-driven workflows can reduce review time and the need for IHC, while expanding into critical tasks such as lymph node evaluation, LVI identification, TILs quantification, and the automated scoring of ER, PR, HER2, and Ki67. Dr. Schnitt concludes that while AI will not replace pathologists, “augmented intelligence”—the combination of a pathologist with AI—is superior to either alone, providing a more consistent and accurate diagnostic process that reduces overall workload and shortens turnaround times.